Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197843 | 0.82 | EZH2 (0.73) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL19620738 | 0.79 | EZH2 (0.54) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL19620906 | 0.75 | EZH2 (0.52) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL31124661 | 0.69 | EZH2 (0.82) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL23030221 | 0.69 | EZH2 (0.62) | EZH2BRD4EZH1BRD2BRD3 | |
| SCHEMBL21423087 | 0.68 | EZH2 (1.00) | EZH2EZH1 | |
| SCHEMBL19621002 | 0.66 | EZH2 (0.46) | EZH2BRD4EZH1 | |
| SCHEMBL20111816 | 0.65 | EZH2 (0.53) | EZH2 | |
| SCHEMBL21863170 | 0.64 | EZH2 (0.45) | EZH2EZH1 | |
| SCHEMBL19620816 | 0.64 | EZH2 (0.48) | EZH2EZH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH2 2/4885BRD4 186/4885EZH1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.